Advice
following an abbreviated submission:
midazolam oral solution (Ozalin®) is accepted for use within NHSScotland.
Indication under review: in children from 6 months to 17 years old, for moderate sedation before a therapeutic or diagnostic procedure or as premedication before anaesthesia.
Ozalin® 2mg/mL oral solution is supplied in single-use glass ampoules and the dose must be measured using the oral applicator, which is graduated in kg of body weight, and the filter straw provided.
The availability of midazolam oral solution (Ozalin®) provides a licensed alternative to an unlicensed preparation.
Download detailed advice617KB (PDF)
Medicine details
- Medicine name:
- midazolam (Ozalin)
- SMC ID:
- SMC2392
- Indication:
in children from 6 months to 17 years old, for moderate sedation before a therapeutic or diagnostic procedure or as premedication before anaesthesia.
- Pharmaceutical company
- Primex Pharmaceuticals
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 October 2021